[Exogenous phosphocreatine in the prevention and treatment of cardiac insufficiency in patients with myocardial infarction].
Central, intracardiac hemodynamics and myocardial contractility were assessed in 97 inpatients with macrofocal myocardial infarction. Of them, 71 received conventional chemotherapy versus 26 patients given additionally intravenous phosphocreatine (neoton). The total dose of neoton 30 g was injected during the course of 6 days following the disease onset. With minimal changes in central hemodynamics, phosphocreatine was found to prevent left-ventricular dilatation and development of congestive heart failure by decreasing preload, to maintain myocardial contractility without reduction.
Perepech
N B
NB
Nedoshivin
A O
AO
Kutuzova
A E
AE
D000328:Adult; D000368:Aged; D002303:Cardiac Output, Low / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy*; D010725:Phosphocreatine / Q000494:pharmacology / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects
D010725:Phosphocreatine
Profilaktika i lechenie serdechnoĭ nedostatochnosti u bolńykh infarktom miokarda s pomoshchíu ékzogennogo fosfokreatina.